← Back to Search

Diuretic

Diuretics for Chronic Kidney Disease

Phase 2

Recruiting

Research Sponsored by Stanford University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Stable dialysis patients who produce urine and able to provide consent

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up change from baseline quality of life score at 1 week for each study arm

Awards & highlights

Study Summary

This trial will study how well diuretics work in patients with chronic kidney disease.

Who is the study for?

This trial is for stable chronic kidney disease patients who can consent, including those on dialysis but still producing urine. It's not for those recently hospitalized or with unstable food intake, nor for anyone using antibiotics in the last two months or expecting to use them.Check my eligibility

What is being tested?

The study tests the effectiveness of a diuretic called Metolazone compared to a placebo in managing chronic kidney disease. Participants will be randomly assigned to receive either the medication or an inactive substance.See study design

What are the potential side effects?

Metolazone may cause dehydration, electrolyte imbalances (like low potassium), low blood pressure, dizziness, and increased urination which could affect kidney function.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am on stable dialysis, can still urinate, and can give consent.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ change from baseline urine output at 1 week for each study arm

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~change from baseline urine output at 1 week for each study arm

This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline urine output at 1 week for each study arm for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in urine output

Secondary outcome measures

Change in kidney clearance of uremic solutes

Change in quality of life questionnaire score

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Metolazone then placeboActive Control1 Intervention

Metolazone will be taken orally during the first week, followed by washout of 1-2 weeks, then placebo will be taken the following week.

Group II: Placebo then MetolazonePlacebo Group1 Intervention

Placebo will be taken orally during the first week, followed by washout of 1-2 weeks, then metolazone will be taken the following week.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor

2,395 Previous Clinical Trials

17,341,545 Total Patients Enrolled

Media Library

Metolazone (Diuretic) Clinical Trial Eligibility Overview. Trial Name: NCT04542304 — Phase 2

Chronic Kidney Disease Research Study Groups: Placebo then Metolazone, Metolazone then placebo

Chronic Kidney Disease Clinical Trial 2023: Metolazone Highlights & Side Effects. Trial Name: NCT04542304 — Phase 2

Metolazone (Diuretic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04542304 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What types of ailments is this therapy generally employed to address?

"This medical intervention is useful for those with kidney diseases, hypertension and fluid retention."

Answered by AI

What is the enrollment capacity for this clinical research?

"Affirmative. According to the information hosted on clinicaltrials.gov, recruitment for this medical trial is underway; it was initially posted in March 2021 and last revised September 2022. Fifty participants are sought from two different healthcare facilities."

Answered by AI

Has this procedure achieved official endorsement from the FDA?

"Our assessment of this treatment's safety is a 2, as it has yet to reach Phase 3 and demonstrate efficacy in clinical trials. However, existing data does indicate that the medication is safe for use."

Answered by AI

Is recruitment for this experiment ongoing?

"Affirmative. The clinicaltrials.gov database shows that this medical experiment, posted on March 1st 2021 and amended September 29th 2022, is actively seeking out volunteers. Fifty participants must be sourced from two different locations."

Answered by AI

Has this treatment method been examined in prior clinical experiments?

"At present, there are 2 active trials for this treatment but none of them have reached Phase 3 yet. Principal sites offering these clinical studies can be found in New Haven, Connecticut with additional locations participating as well."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Efficacy of Diuretics in Kidney Disease

Tammy Lisa Sirich 2021. "Efficacy of Diuretics in Kidney Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04542304.

All > Kidney Failure